| pubmed-article:9670669 | pubmed:abstractText | Results are submitted of study of the effectiveness of inclusion into the treatment program for patients with chronic lymphoid leukemia of specific (thymalin) and unspecific (plasmapheresis) means and modes of immune correction, which made for more rapid attaining clinical and hematological compensation by comparison with chemotherapeutic agents only. Furthermore, the method of combined use of drugs, attempted for the first time, permitted the functional activity of the lymphoid system to be improved, with the clinical and hematological compensation being achieved in a shorter space of time. | lld:pubmed |
